Relapsed/Refractory Solid Cancers | Norton Healthcare

Indication: Relapsed/Refractory Solid Cancers

AN OPEN-LABEL, MULTICENTER, PHASE I STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID CANCERS

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: IGM Biosciences

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.